Moreover, targeting the IDO1/TDO2-kynurenine-AHR pathway to restore potent anti-tumor immune responses is an important goal of cancer immunotherapy [74, 75], which might be highly relevant for HCC and cholangiocarcinoma therapy. Here, IDO1 is linked to neoplasm.